Related Experiment Video
Updated: Jun 7, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Neoadjuvant Chemoimmunotherapy in Resectable NSCLC With PD-L1 Expression < 1%: A Systematic Review and Network
Isadora Mamede1, Skyler Taylor2, Rafael Lara Nohmi3
1School of Medicine, Federal University of São João del Rei, Divinópolis, Brazil.
Background:
The benefit of neoadjuvant or perioperative chemoimmunotherapy in resectable non-small cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) expression < 1% remains uncertain, as evidence is largely derived from subgroup analyses. We conducted a systematic review and network meta-analysis to compare the efficacy of individual chemoimmunotherapy regimens in this population.
Patients And Methods:
Randomized controlled trials enrolling patients with resectable NSCLC and reporting outcomes for the PD-L1 < 1% subgroup were identified through searches of PubMed, Embase, and Cochrane CENTRAL. Event-free survival, overall survival, pathological complete response, and major pathological response were evaluated. A Bayesian random-effects network meta-analysis was performed, with treatment ranking using surface under the cumulative ranking curve.
Results:
Eight trials comprising 3387 patients were included, of whom 1012 (29.9%) had PD-L1 < 1%. No chemoimmunotherapy regimen significantly improved event-free survival or overall survival compared with chemotherapy alone. Nivolumab plus chemotherapy was the only regimen associated with a statistically significant improvement in pathological complete response versus chemotherapy (odds ratio 5.88; 95% credible interval 1.41-37.4). No regimen significantly improved major pathological response. Despite the absence of statistically significant survival differences, chemotherapy alone consistently ranked lowest across event-free survival, overall survival, pathological complete response, and major pathological response.
Conclusion:
In resectable NSCLC with PD-L1 < 1%, chemoimmunotherapy improves pathological response but has not yet demonstrated a survival benefit. Among available regimens, nivolumab plus chemotherapy shows the most consistent evidence for enhanced pathological response, although current data do not support the superiority of any single immunotherapy strategy.
